RespireRx Pharmaceuticals Inc (RSPI)

[davidal66]

I dissent eawolfie. Your points are all well taken, but they are not a unified theory of dismay in biotechnology investing. Another factor to consider is how many compounds are tested? how well they are tested in animal toxicologiy testing to make sure the kings are worked out? the depth of your companies' relationship with the FDA and the care and feeding of that relationship? the amount of capital you have on hand to deal with all of these issues as well as hiring top notch people to design and implement trials that finish on time. Many of these factors lead back to the timing of when a pharma deal is done.

So it's not that I take issue with your points: I take issue with how you frame it: it's either's management's fault for lousing it up or it's a bad investment. Perhaps certain technolgies are so complex they should be exploited by a large pharma at an early stage so the proper toxicology tests are done, the proper clinical trials are run, so the relationshp with the FDA is superb and so on. Of course, even if all these data points occur, something unexpected can always crop up.

It is for these reasons, I hope that the neurodegeneration deal will occur with the high impacts in the early part of 2007 as Dr. Stoll has alluded to if things go as he hopes. What possible reason is there to be sitting on a mountain of gold if it remains forever elusive?